3D Structure
ModBase 3D Structure for O14836
Purity/Purification
Greater than 90.0% as determined by SDS-PAGE.
Form/Format
Sterile filtered colorless solution.
TACI a protein solution (0.25mg/ml) contains Phosphate Buffered Saline (pH 7.4), 30% glycerol and 1mM DTT.
Other Notes
Small volumes of TNFRSF13B recombinant protein vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.
Related Product Information for
TNFRSF13B recombinant protein
Description: TACI produced in Sf9 Insect cells is a single, glycosylated polypeptide chain containing 407 amino acids (1-165a.a.) and having a molecular mass of 45.8kDa (Molecular size on SDS-PAGE will appear at approximately 25-50kDa). TACI is expressed with a 242 amino acid hIgG-His tag at C-Terminus and purified by proprietary chromatographic techniques.
Introduction: TNFRSF13B (TACI) is a transmembrane receptor protein found predominantly on the surface of B cells (a significant part of the immune system). TACI was at first discovered owing to its ability to interact with calcium-modulator and cyclophilin ligand (CAML). Later on, it was found that TACI plays a key role in humoral immunity by interacting with two members of the TNF family. Also, TACI controls T cell-independent B cell antibody responses, isotype switching, and B cell homeostasis.
Product Categories/Family for TNFRSF13B recombinant protein
CYTOKINES AND GROWTH FACTORS
NCBI/Uniprot data below describe general gene information for TNFRSF13B. It may not necessarily be applicable to this product.
NCBI Accession #
NP_036584.1
[Other Products]
NCBI GenBank Nucleotide #
NM_012452.2
[Other Products]
UniProt Primary Accession #
O14836
[Other Products]
UniProt Secondary Accession #
Q32LX4; Q7Z6F5; B2R8B0; B7Z6V8[Other Products]
UniProt Related Accession #
O14836[Other Products]
Molecular Weight
19,865 Da[Similar Products]
NCBI Official Full Name
tumor necrosis factor receptor superfamily member 13B
NCBI Official Synonym Full Names
TNF receptor superfamily member 13B
NCBI Official Symbol
TNFRSF13B??[Similar Products]
NCBI Official Synonym Symbols
CVID; RYZN; TACI; CD267; CVID2; IGAD2; TNFRSF14B
??[Similar Products]
NCBI Protein Information
tumor necrosis factor receptor superfamily member 13B
UniProt Protein Name
Tumor necrosis factor receptor superfamily member 13B
UniProt Synonym Protein Names
Transmembrane activator and CAML interactor; CD_antigen: CD267
Protein Family
Tumor necrosis factor receptor superfamily
UniProt Gene Name
TNFRSF13B??[Similar Products]
UniProt Synonym Gene Names
TACI??[Similar Products]
NCBI Summary for TNFRSF13B
The protein encoded by this gene is a lymphocyte-specific member of the tumor necrosis factor (TNF) receptor superfamily. It interacts with calcium-modulator and cyclophilin ligand (CAML). The protein induces activation of the transcription factors NFAT, AP1, and NF-kappa-B and plays a crucial role in humoral immunity by interacting with a TNF ligand. This gene is located within the Smith-Magenis syndrome region on chromosome 17. [provided by RefSeq, Jul 2008]
UniProt Comments for TNFRSF13B
TNFRSF13B: Receptor for TNFSF13/APRIL and TNFSF13B/TALL1/BAFF/BLYS that binds both ligands with similar high affinity. Mediates calcineurin-dependent activation of NF-AT, as well as activation of NF-kappa-B and AP-1. Involved in the stimulation of B- and T- cell function and the regulation of humoral immunity. Defects in TNFRSF13B are the cause of immunodeficiency common variable type 2 (CVID2). CVID2 is a primary immunodeficiency characterized by antibody deficiency, hypogammaglobulinemia, recurrent bacterial infections and an inability to mount an antibody response to antigen. The defect results from a failure of B-cell differentiation and impaired secretion of immunoglobulins; the numbers of circulating B-cells is usually in the normal range, but can be low. Defects in TNFRSF13B are a cause of immunoglobulin A deficiency 2 (IGAD2). Selective deficiency of immunoglobulin A (IGAD) is the most common form of primary immunodeficiency, with an incidence of approximately 1 in 600 individuals in the western world. Individuals with symptomatic IGAD often have deficiency of IgG subclasses or decreased antibody response to carbohydrate antigens such as pneumococcal polysaccharide vaccine. Individuals with IGAD also suffer from recurrent sinopulmonary and gastrointestinal infections and have an increased incidence of autoimmune disorders and of lymphoid and non-lymphoid malignancies. In vitro studies have suggested that some individuals with IGAD have impaired isotype class switching to IgA and others may have a post-switch defect. IGAD and CVID have been known to coexist in families. Some individuals initially present with IGAD1 and then develop CVID. These observations suggest that some cases of IGAD and CVID may have a common etiology. 2 isoforms of the human protein are produced by alternative splicing.
Protein type: Cell cycle regulation; Membrane protein, integral; Receptor, misc.
Chromosomal Location of Human Ortholog: 17p11.2
Cellular Component: plasma membrane
Molecular Function: protein binding; receptor activity
Biological Process: B cell homeostasis; cell surface receptor linked signal transduction; hemopoietic progenitor cell differentiation; negative regulation of B cell proliferation; tumor necrosis factor-mediated signaling pathway
Disease: Immunodeficiency, Common Variable, 2; Immunoglobulin A Deficiency 2
Research Articles on TNFRSF13B
1. genetic polymorphism is associated with hypogammaglobulinemia and systemic lupus erythematosis in a family with common variable immunodeficiency disorder
Precautions
All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.
Disclaimer
While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.
It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.